Sector Update: Health Care Stocks Mostly Lower; Regulators OK Expanded Use of Protalix Medication for Gaucher Disease


Shutterstock photo

Top Healthcare Stocks

JNJ -0.28%

PFE -0.02%

ABT -0.47%

MRK -0.37%

AMGN +0.72%

Healthcare stocks were posting slim losses Thursday with the NYSE Healthcare Sector Index declining about 0.1% and shares of healthcare companies in the S&P 500 down less than 0.1% as a group.

In company news, Protalix BioTherapeutics Inc. ( PLX ) rallied after the U.S. Food and Drug Administration (FDA) approved its Elelyso injection to also treat pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease.

The agency previously approved the replacement therapy developed by RLX in collaboration with Pfiser ( PFE ) for use in older patients with the genetic disease causing fatty substances to accumulate in cells and certain organ.

PLX shares were ahead about 9.5% in late trade at $2.64 apiece, earlier climbing to a session high of $3.00 a share. The stock has traded within a 52-week range of $2.35 to $5.60 a share, declining over 53% over the past 12 months.

PFE recently was down 0.2% at $29.43 a share.

In other sector news,

(+) RPRX, Said its Androxal testosterone-replacement oral drug outperformed an FDA-approved gel and a placebo in the first of two identical studies, with patients taking Androxal achieved higher sperm concentrations than those in other study arms.

(-) IG, Receives Outperform rating in new coverage today at Oppenheimer.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2014 All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing Commodities
Referenced Stocks: PLX , PFE

More from MT Newswires


MT Newswires

MT Newswires

Market News, Commodities
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by